Quick Answer
Esperion Therapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $403.14 million for the year ending 2025.
- Esperion Therapeutics, Inc. showed an increase of +21.3% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Esperion Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Historical annual values: Fiscal year 2025: $403.14 million | Fiscal year 2024: $332.31 million | Fiscal year 2023: $116.33 million | Fiscal year 2022: $75.48 million | Fiscal year 2021: $78.45 million | Fiscal year 2020: $227.55 million | Fiscal year 2019: $148.36 million | Fiscal year 2018: $0.00.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: